Cygnal Therapeutics
Cambridge
About Cygnal Therapeutics
Cygnal Therapeutics is developing drugs to manipulate Exoneural Biology for the treatment of cancer, immunological diseases, and regenerative processes. Powered by a comprehensive, cutting-edge neurotechnology platform, They are discovering new dimensions of neural function. Cygnal was founded by Flagship Pioneering in the VentureLabs innovation foundry.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $50K – $100K
- Total funding: $65.0M
- Last round: Series Unknown (Oct 2019)
- Website: cygnaltx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cygnal-therapeutics-61110 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.